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metastasis was identified in 3 of the 22 patients (13.6%), 
and none of the 3 patients with N1 or N2 disease had false-
negative SLNs. SLN identification might be an indicator of 
whether or not MLND should be performed during pulmo-
nary metastasectomy. However, further large-volume and 
multi-institutional studies are needed.
Keywords Cancers metastatic to the lung · 
Metastasectomy · Mediastinal lymph node dissection
Introduction
The lung is one of the most common sites of distant metas-
tasis of solid tumors because the pulmonary arterial vas-
cular bed is the first filter in the hematogenous route [1]. 
More than 30% of extra-thoracic malignances give rise to 
pulmonary metastasis during the course of the disease, and 
approximately 20% of these cases feature metastases that 
are confined to the lungs [2].
Pulmonary metastasis represents terminal systemic dis-
ease; hence, chemotherapy has been the mainstay of thera-
peutic intervention in the majority of cases [3]. However, 
surgical resection of pulmonary metastasis is sometimes 
necessary for pathological confirmation, and complete sur-
gical excision of all pulmonary deposits is often technically 
feasible with low morbidity and mortality. Improvement of 
surgical techniques such as parenchymal-sparing resection, 
development of more effective chemotherapy regimens, 
and significantly increased long-term survival as observed 
in retrospective studies have resulted in pulmonary metas-
tasectomy gradually becoming a standard therapeutic pro-
cedure in properly selected patients [1, 4]. The theoretical 
basis of local treatment, such as surgery with a curative 
intent, for metastatic tumor is the “cascade-spreading 
Abstract This is the first study to evaluate the feasibil-
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through segmentectomy or lobectomy with MLND owing 
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operation, the radioactivity of the lymph nodes (ex vivo) 
was counted with a handheld gamma probe after MLND. 
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tomy, in 5 patients. The number of dissected lymph nodes 
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the SLN could be detected, and the number of SLNs identi-
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process” of cancer cells to other organs. Even with hema-
togenous metastasis, there may be a presystemic stage, that 
is, tumor spread limited to “key-site” organs such as the 
liver or lung [5, 6].
The incidence of thoracic lymph node involvement 
in pulmonary metastasis ranges from 5 to 66.3%, and the 
presence of lymph node metastasis is a significant factor for 
worse prognosis [7, 8]. The addition of mediastinal lymph 
node dissection (MLND) to pulmonary metastasectomy 
remains controversial, because its therapeutic efficacy is 
insufficient and it is associated with a longer operation time 
[9]. However, local recurrence seems to decrease when 
MLND is performed during pulmonary metastasectomy 
[10, 11]. Additionally, performing lymph node dissection 
or sampling can reveal unexpected lymph node involve-
ment and provide useful information for postoperative ther-
apeutic decisions [7, 12].
The sentinel lymph node (SLN) is the first pass of lym-
phatic drainage for cancer cells and is the key lymph node 
for acquiring information regarding the presence of metas-
tasis from the primary tumor. If metastasis in the SLN is 
not identified, it is possible to avoid unnecessary lymph 
node dissection [13]. SLN biopsy has become a standard 
procedure in the treatment of early stage breast cancer and 
melanoma as a way to avoid the complications of lymph 
node dissection. Although the application of SLN mapping 
to lung cancer surgery has remained controversial, it could 
be helpful in deciding whether omission of MLND is possi-
ble or whether segmentectomy is indicated in patients with 
clinically node negative disease [14].
The hypothesis of this study was that regional lymph 
node metastasis in patients with cancers metastatic to the 
lung occurs in a manner similar to lymph node metastasis 
in primary lung cancer; hence, SLN identification might be 
an indicator of whether MLND should be performed or not 
during pulmonary metastasectomy. However, it is unclear 
whether SLN identification has the same significance in the 
setting of hematogenous spread of an extrathoracic primary 
cancer. This is the first study to evaluate the feasibility of 
MLND based on SLNs during pulmonary metastasectomy 
in patients with clinically node negative cancers metastatic 
to the lung.
Materials and methods
Candidates for this study included patients who underwent 
pulmonary metastasectomy with MLND with a curative 
intent for cancers metastatic to the lung between March 
2008 and November 2013 at the Korea University Guro 
Hospital. After approval by the Ethics Committee of the 
institution, written informed consent was obtained from 
all patients in accordance with the Declaration of Helsinki 
(KUGH14230-001).
For preoperative assessment, each patient underwent 
thoracic computed tomography (CT) scanning, positron 
emission tomography (PET/CT), and a pulmonary func-
tion test. In principle, the diagnosis and treatment plan for 
pulmonary metastasis were confirmed by a multidiscipli-
nary tumor board including thoracic surgeons, radiologists, 
nuclear medicine specialists, and medical oncologists. Pul-
monary metastasis was diagnosed on the basis of tissue 
confirmation through percutaneous needle biopsy under 
CT-guidance, or on the basis of radiologic confirmation 
through revaluation after an observation period of at least 2 
months after initial diagnosis.
The inclusion criteria in this study followed the basic 
principles for selecting patients to undergo pulmonary 
metastasectomy, which were technical resectability, toler-
able general and functional surgical risk, control of the pri-
mary tumor, and no further extrathoracic metastasis [15]. 
Patients who had received chemotherapy before pulmonary 
metastasectomy as neoadjuvant chemotherapy for pulmo-
nary metastasis or repeat pulmonary metastasectomy were 
not included. In addition, patients with suspicion of metas-
tasis in the hilar or mediastinal lymph nodes as observed on 
CT or PET/CT were excluded from this study. Mediastino-
scopic or endobronchial ultrasonic mediastinal LN biopsy 
was not performed in any patient. Patients with a single 
pulmonary metastasis or multiple metastases in the same 
lobe were included, but patients with multiple metastases in 
different lobes were excluded.
In our hospital, when a metastasis is located at the 
peripheral lung and there is no evidence of other pulmo-
nary metastasis, in most cases, we attempt to apply a mini-
mally invasive surgical approach such as video-assisted 
thoracoscopic (VATS) wedge resection after preoperative 
localization under CT guidance [16, 17]. MLND is not per-
formed in these patients in order to minimize complications 
after surgery. However, when the metastasis is located in 
the central lung, and the resection margin is supposed to be 
more than 2  cm, segmentectomy is performed. When the 
resection margin is not sufficient in centrally located metas-
tases, or there is a large tumor or multiple metastases in the 
same lobe, lobectomy is chosen. VATS major pulmonary 
resection is performed, regardless of etiology, when the 
lesion is amenable to anatomic resection and the patient can 
tolerate single lung ventilation, as determined by preopera-
tive pulmonary function tests in our institution [18, 19]. 
VATS was not performed in cases of a definite pleural cal-
cification, tight calcification adherent to a pulmonary ves-
sel, thoracic cage deformity, decreased ipsilateral lung vol-
ume, a tumor 6 cm or larger, an invasive mediastinal tumor, 
or the inability to completely resect the lesion. Eventually, 
patients who underwent segmentectomy or lobectomy as 
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well as complete MLND by VATS or standard thoracotomy 
were included in this study.
The methods of radioisotope injection and intraoperative 
SLN mapping were the same as in previous studies [20, 
21]. A total dose of 1 mCi of radiotracer (99m Tc-mannosyl 
human serum albumin; MSA or 99m Tc-phytate) in 0.2 ml 
was administered at the peritumoral region under chest CT 
guidance approximately 1 h before surgery in the CT room, 
or soon after placing ports for video-assisted thoracoscopic 
surgery or standard thoracotomy during surgery according 
to the availability of the CT room on the day of surgery. 
When patients had multiple metastases in the same lobe, 
radiotracer was injected at the largest lesion. Radioactiv-
ity in the lymph nodes was counted after dissection with 
a handheld gamma probe (Neo2000; Johnson & Johnson, 
Cincinnati, OH). SLN was defined as any node for which 
the count was five times the radioactivity of the resected 
lung tissue with the lowest count. All collected lymph 
nodes including SLNs were cut into 2 mm slices and diag-
nosed from formalin-fixed and paraffin-embedded sections 
stained with hematoxylin and eosin.
Statistical analysis
The identification rate was defined as the percentage of 
patients with detected SLNs among the entire analyzed 
group. The false-negative rate for SLN identification was 
assessed by the presence of metastatic lymph nodes not 
identified as SLNs, with the labeled SLNs histologically 
appearing uninvolved. A p value of <0.05 was considered 
statistically significant. Statistical software (SPSS for Win-
dows, version 22.0; SPSS, Chicago, IL) was used for statis-
tical analysis.
Results
A total of 22 patients (16 men, 6 women) were enrolled 
in this study, and their mean age was 63.3 ± 7.01 years 
(range 52–76). The primary lesions of cancers meta-
static to the lung involved the rectum (adenocarcinoma) 
in 8 patients, the colon (adenocarcinoma) in 8 patients, 
the kidney (renal cell carcinoma) in 2 patients, the skin 
(malignant granular cell tumor) in 1 patient, the thigh 
(sarcoma) in 1 patient, the thyroid (papillary carcinoma) 
in 1 patient, and the endometrium (adenocarcinoma) in 1 
patient (Table 1). The pulmonary metastases were located 
in the right upper lobe in 4 patients, right middle lobe in 
4 patients, right lower lobe in 9 patients, left upper lobe 
in 3 patients, and left lower lobe in 2 patients. Lobectomy 
was performed in 17 patients, and segmentectomy, in 5 
patients. All patients had a single pulmonary metasta-
sis, except 2 patients who had multiple metastases in the 
same lobe and underwent lobectomy. The size of the pul-
monary metastasis was 2.7 ± 1.90 cm (0.9–7.5).
The number of dissected lymph nodes per patient was 
14.4 ± 8.69 (range 5–36) (Table  2). In all patients, the 
SLN could be detected (SLN identification rate, 100%), 
and the number of SLNs identified was 2.0 ± 1.15 (range 
1–5) per patient. SLNs were detected at the mediastinal 
lymph node station in 17 out of 22 patients (77.3%), and 
at the hilar lymph node station in 14 out of 22 patients 
(63.6%). Eight out of 22 patients (36.4%) had SLNs only 
in the mediastinum, 5 patients (22.7%) had SLNs only 
in the hilar lymph node station, and 9 patients (40.9%) 
had SLNs in both the mediastinal and hilar lymph node 
stations. The distribution of mediastinal SLNs is shown 
in Fig.  1. In 19 out of 22 patients (86.4%), mediastinal 
SLNs were located in a lobe specific area. In 3 patients 
(13.6%), mediastinal SLNs were located in the non-lobe 
specific area; one patient with cancer metastatic to the 
lung, involving the right upper lobe, had a SLN at the 
inferior pulmonary ligament, one patient with metastasis 
in the right upper lobe had a SLN at the subcarinal area, 
and one patient with metastasis in the left upper lobe had 
a SLN in the subcarinal area.
Table 1  Patient characteristics
Data are presented as n or mean ± standard deviation (range)
VATS  video-assisted thoracoscopic surgery
Characteristic No.
Sex (Male/Female) 16/6




 Kidney (renal cell carcinoma) 2
 Skin (malignant granular cell tumor) 1
 Thigh (sarcoma) 1
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Lymph node metastasis was identified in 3 of the 22 
patients (13.6%), and skipped metastasis was not noted 
in any case (Table 3). Among the 3 patients, lymph node 
metastases were found at lobe-specific areas in 2 patients, 
but one patient with clinical stage T3N0M0 disease had 
metastasis in a non-lobe specific mediastinal lymph node as 
well as in a lobe specific mediastinal lymph node. However, 
none of the 3 patients with N1 or N2 disease had false-neg-
ative SLNs.
No complications were observed during the SLN map-
ping procedure. There was no mortality or major periopera-
tive morbidity, only minor complications such as prolonged 
air leak in 2 patients (0.9%) and pneumonia in 1 (0.5%).
During the follow-up period (41.5 ± 26.1 months), 
the 3-years thoracic recurrence-free rate was 43.5% in all 
patients, and there was a potential difference between path-
ologically lymph node positive and negative cases (54.4% 
in node negative cases vs. 33.3% in node positive, p = 0.07) 
(Fig.  2). The 3-year overall survival rate was 70.6% in 
all patients, and there was a potential difference between 
Table 2  Results of SLN identification
Data are presented as n or mean ± standard deviation (range)
SLN sentinel lymph node
Characteristic No.
Dissected LN (No.) 14.4 ± 8.69 (5–36)
SLN detection rate (%) 100 (22/22)
No. of SLNs 2.0 ± 1.15 (1–5)
Metastasis (no. of patients) 3/22 (13.6%)
False-negative SLNs (%) 0
Fig. 1  Distribution of sentinel 
nodes according to tumor loca-
tion. a Right upper lobe, b right 
middle lobe, c right lower lobe, 
d left upper lobe, e left lower 
lobe. In patients with a meta-
static lung cancer in the right 
upper lobe, positive sentinel 
nodes were mostly detected in 
the paratracheal and interlobar 
lymph nodes (10/12, 83.3%). 
Two sentinel nodes (16.7%) 
were not located in lobe-specific 
areas such as the subcarinal and 
inferior pulmonary ligament 
area. Metastases were found 
only in non-lobe specific areas
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pathologically lymph node positive and negative cases 
(77.0% in node negative cases vs. 33.3% in node positive, 
p = 0.05).
Discussion
MLND may contribute to complete carcinologic control 
and more accurate patient prognosis, which allows for cus-
tomized adjuvant treatment even in patients with thoracic 
lymph node involvement during pulmonary metastasec-
tomy [10]. However, the presence of clinical or pathologi-
cal lymphadenopathy is still believed to be a relative or 
absolute contraindication to pulmonary metastasectomy by 
most thoracic surgeons [22], because the presence of lymph 
node metastasis is a significant and independent poor prog-
nostic factor in patients with pulmonary metastasis [7, 11, 
12]. Moreover, the role of MLND during pulmonary metas-
tasectomy has not been established because its prognostic 
significance is controversial.
The policy of our hospital is that patients with suspi-
cion of metastasis in the hilar or mediastinal lymph nodes 
as observed on preoperative CT or PET/CT are not candi-
dates for pulmonary metastasectomy. However, preopera-
tive imaging, such as CT or PET/CT, is limited in deter-
mining the presence of metastasis in thoracic lymph nodes, 
and Seebacher et  al., reported that MLND during pulmo-
nary metastasectomy revealed unexpected lymph node 
involvement in 17% of patients with clinically negative 
lymph nodes [12]. Kudelin et  al. recommend MLND for 
every patient due to the high prevalence of thoracic lymph 
node involvement [23]. Given the limitations of these pre-
operative imaging techniques and the positive impact of 
subsequent treatment, MLND at the time of metastasec-
tomy appears reasonable in patients suspected to have no 
thoracic lymph node involvement [12, 13]. However, care-
ful consideration of the need for MLND is required in all 
patients, because of the increased morbidity and decreased 
quality of life associated with it. It is thus important for 
intraoperative decision making regarding MLND to be per-
formed for each patient with pulmonary metastatic disease.
To reduce unnecessary lymph node dissection, many 
feasibility studies of MLND based on SLN have been 
conducted for primary lung cancer [24, 25], and we have 
extensive experience in SLN mapping [14, 20, 26]. We 
hypothesized that SLN identification might be an indica-
tor of whether or not MLND should be performed during 
pulmonary metastasectomy if regional lymph node metas-
tasis in cancers metastatic to the lung occurs in a manner 
similar to lymph node metastasis in primary lung cancer. 
However, it is unclear whether SLN identification has the 
same significance in the setting of hematogenous spread of 
an extrathoracic primary cancer.
In this study, SLN was identified in all cases, and 
lymph node metastasis was found only in SLNs (no false 
positives). This result indicates that SLNs identified 
Table 3  Characteristics of 
the patients with lymph node 
metastasis during pulmonary 
metastasectomy
SLN  sentinel lymph node
Sex Age (years) Primary cancer Affected lobe Tumor size 
(cm)
SLN station Metastatic 
LN station
Female 60 Rectum Right upper 4 9, 11, 12 11
Male 73 Colon Right lower 7.5 4 4, 7, 10
Male 56 Colon Right lower 3.5 7 7, 11
Fig. 2  The 3-year thoracic recurrence-free rate and overall survival 
rate after pulmonary metastasectomy with mediastinal lymph node 
dissection in clinically node negative patients. The 3 years thoracic 
recurrence-free rate and overall survival rate was 43.5 and 70.6%, 
respectively. There were potential differences between pathologically 
lymph node positive and negative cases
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during pulmonary metastasectomy alone might pos-
sibly be metastatic; hence, the decision regarding the 
performance of MLND could be made during surgery. 
Furthermore, lymph node sampling or dissection could 
provide more accurate staging and be used to deter-
mine the appropriate adjuvant treatment, but the effects 
of sampling and dissection on long term survival do 
not significantly differ [7, 10, 12]. Therefore, obtaining 
only the SLN during pulmonary metastasectomy might 
be sufficient to gain accurate information regarding dis-
ease status and similar long term survival comparing to 
MLND. Although lymph node metastasis was identified 
in 3 patients and skipped metastasis was not noted in any 
patient (0%) in this study, Pfannschmidt et  al. reported 
that 16.3% (13/45) of patients had mediastinal noncon-
tiguous lymph node spread [27]. However, a large-scale 
study is needed to address this issue in the future.
This study has many limitations, including the small 
number of patients, heterogeneity of the primary cancers, 
the single center experience, and the fact that patients 
who underwent wedge resection were not included. These 
limitations should be taken into consideration when inter-
preting the results of this study.
In conclusion, SLN identification might be an indica-
tor of whether or not MLND should be performed during 
pulmonary metastasectomy. However, further large-vol-
ume and multi-institutional studies are needed to confirm 
this finding.
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